ENTA Enanta Pharmaceuticals Inc.

+0.29  (+0%)
Previous Close 81.79
Open 81.8
Price To Book 3.7
Market Cap 1,614,491,110
Shares 19,669,726
Volume 6,996
Short Ratio
Av. Daily Volume 190,836

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 preliminary data June 14, 2019 met primary endpoint.
Respiratory Syncytial Virus
Phase 2 initial data due 3Q 2019.
Non-alcoholic steatohepatitis (NASH)
Phase 2 enrollment to continue through 2019.
Primary biliary cholangitis (PBC)
Approval announced August 3, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
Phase 2b ongoing. Data released November 2015. Phase 3 initiated
Approved December 19, 2014.
HCV - genotype 1
Approved July 25, 2017.
VIEKIRA PAK - once-daily, fixed-dose formulation through Abbvie
HCV - genotype
Phase 1 trial initiation announced July 8, 2019.
Hepatitis B virus (HBV)

Latest News

  1. Enanta Pharmaceuticals to Host Conference Call on August 6 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2019
  2. Enanta Pharmaceuticals (ENTA) Upgraded to Strong Buy: Here's What You Should Know
  3. Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus (HBV)
  4. Enanta's Respiratory Virus Drug Aces Midstage Study
  5. How Much Did Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Pocket Last Year?
  6. UPDATE 1-Enanta's lung infection therapy succeeds in mid-stage trial
  7. Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV)
  8. Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
  9. AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies
  10. AbbVie's MAVIRET™ now listed in New Brunswick
  11. Edited Transcript of ENTA earnings conference call or presentation 7-May-19 8:30pm GMT
  12. Do Enanta Pharmaceuticals's (NASDAQ:ENTA) Earnings Warrant Your Attention?
  13. Enanta Pharmaceuticals to Present at Upcoming Investor Conference
  14. Enanta Pharmaceuticals, Inc. (ENTA) Q2 2019 Earnings Call Transcript
  15. Enanta Pharmaceuticals (ENTA) Beats Q2 Earnings Estimates
  16. Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot
  17. Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019
  18. Here’s What Hedge Funds Think About Enanta Pharmaceuticals Inc (ENTA)
  19. Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
  20. Enanta Pharmaceuticals to Host Conference Call on May 7th at 4:30 pm ET to Discuss Its Financial Results for Its Fiscal Second Quarter Ended March 31, 2019